Publications by authors named "Isabel Beresford"

Claim this Profile
A
A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.
Richard A Grove, Conn M Harrington, Andreas Mahler, Isabel Beresford, Paul Maruff

Curr Alzheimer Res· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of the benzazepine class of histamine H3 receptor antagonists.
David M Wilson, James Apps, Nicholas Bailey, Mark J Bamford, Isabel J Beresford

Bioorg Med Chem Lett· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.
David M Wilson, James Apps, Nicholas Bailey, Mark J Bamford, Isabel J Beresford

Bioorg Med Chem Lett· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.
Andrew D Medhurst, Alan R Atkins, Isabel J Beresford, Kim Brackenborough, Michael A Briggs

J Pharmacol Exp Ther· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatments for stroke.
Isabel J Beresford, Andrew A Parsons, A Jacqueline Hunter

Expert Opin Emerg Drugs· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis